MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ejh.14170

Медицинская библиотека · European journal of haematology · 2024

Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.

Mellinghoff Sibylle C, Robrecht Sandra, Sprute Rosanne, Mayer Leonie, Weskamm Leonie M, Dahlke Christine, Gruell Henning, Teipel Finn, Schlößer Hans A, Siepmann Klara, Thelen Martin, Fink Anna-Maria, Fischer Kirsten, Klein Florian, Addo Marylyn M, Kolovou Androniki, Cornely Oliver A, Eichhorst Barbara, Hallek Michael, Langerbeins Petra

Наблюдательное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Preventing severe COVID-19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS-CoV-2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL).

METHODS/

RESULTS

Blood samples of six patients with CLL were collected 55 days after fourth COVID-19 vaccination. All patients had a SARS-CoV-2 infection within 12 months before the second booster (fourth vaccination). SARS-CoV-2 spike receptor binding domain (RBD)-specific IgG antibodies were detectable in 6/6 (100.0%) CLL patients after four compared to 4/6 (66.7%) after three vaccinations. The median number of SARS-CoV-2 spike-specific T cells after repeated booster vaccination plus infection was 166 spot-forming cells (SFC) per million peripheral blood mononuclear cells. Overall, 5/5 (100%) studied patients showed a detectable increase in T cell activity.

CONCLUSION

Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID-19 vaccination combined with SARS-CoV-2 infection, even in those undergoing B cell-depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants.

Для цитирования: Mellinghoff Sibylle C, Robrecht Sandra, Sprute Rosanne, Mayer Leonie, Weskamm Leonie M, Dahlke Christine, Gruell Henning, Teipel Finn, Schlößer Hans A, Siepmann Klara, Thelen Martin, Fink Anna-Maria, Fischer Kirsten, Klein Florian, Addo Marylyn M, Kolovou Androniki, Cornely Oliver A, Eichhorst Barbara, Hallek Michael, Langerbeins Petra. Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.. European journal of haematology. 2024. DOI: 10.1111/ejh.14170.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.